Literature DB >> 26772773

Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions.

Mercè Mateu-Jiménez1,2, Albert Sánchez-Font1,2, Alberto Rodríguez-Fuster3, Rafael Aguilό3, Lara Pijuan4, Clara Fermoselle1,2, Joaquim Gea1,2, Victor Curull1,2, Esther Barreiro1,2.   

Abstract

Chronic respiratory diseases such as obstructive pulmonary disease (COPD) and oxidative stress may underlie lung cancer (LC). We hypothesized that the profile of oxidative and antioxidant events may differ in lung tumors and blood compartments of patients with non-small cell LC (NSCLC) with and without COPD. Redox markers (immunoblotting, ELISA, chemiluminescence, 2D electrophoresis and proteomics) were analyzed in blood samples of 17 control subjects and 80 LC patients (59 LC-COPD and 21 LC) and lung specimens (tumor and nontumor) from those undergoing thoracotomy (35 patients: 23 LC-COPD and 12 LC). As smoking history was more prevalent in LC-COPD patients, these were further analyzed post hoc as heavy and moderate smokers (cutoff, 60 pack-years). Malondialdehyde (MDA)-protein adducts and SOD1 levels were higher in tumor and nontumor samples of LC-COPD than in LC. In tumors compared with nontumors, SOD2 protein content was greater, whereas catalase levels were decreased in both LC and LC-COPD patients. Blood superoxide anion levels, protein carbonylation and nitration were greater in LC and LC-COPD patients than in the controls, and in the latter patients compared with the former. Systemic superoxide anion, protein carbonyls and nitrotyrosine above specific cutoff values best identified underlying COPD among all patients. Smoking did not influence the study results. A differential expression profile of oxidative stress markers exists in blood and, to a lesser extent, in the tumors of LC-COPD patients. These findings suggest that systemic oxidative stress and lung antioxidants (potential biomarkers) may predispose patients with chronic respiratory diseases to a higher risk for LC.

Entities:  

Year:  2016        PMID: 26772773      PMCID: PMC5004710          DOI: 10.2119/molmed.2015.00199

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  52 in total

Review 1.  Factors contributing to the outcome of oxidative damage to nucleic acids.

Authors:  Mark D Evans; Marcus S Cooke
Journal:  Bioessays       Date:  2004-05       Impact factor: 4.345

Review 2.  Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids.

Authors:  Jean Cadet; Steffen Loft; Ryszard Olinski; Mark D Evans; Karol Bialkowski; J Richard Wagner; Peter C Dedon; Peter Møller; Marc M Greenberg; Marcus S Cooke
Journal:  Free Radic Res       Date:  2012-02-22

3.  Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabonomics and proteomics.

Authors:  Jette F Young; Lotte B Larsen; Anders Malmendal; Niels Chr Nielsen; Ida K Straadt; Niels Oksbjerg; Hanne C Bertram
Journal:  J Int Soc Sports Nutr       Date:  2010-02-04       Impact factor: 5.150

Review 4.  Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Authors:  Marc Miravitlles; Myriam Calle; Juan José Soler-Cataluña
Journal:  Arch Bronconeumol       Date:  2011-12-22       Impact factor: 4.872

5.  Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study.

Authors:  Maria Victorina López Varela; María Montes de Oca; Ronald Halbert; Adriana Muiño; Carlos Tálamo; Rogelio Pérez-Padilla; José Roberto B Jardim; Gonzalo Valdivia; Julio Pertuzé; Ana María B Menezes
Journal:  Arch Bronconeumol       Date:  2013-07-13       Impact factor: 4.872

6.  Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response.

Authors:  Abhilasha Gupta; Shruti Srivastava; Rajendra Prasad; Shanker M Natu; Balraj Mittal; Mahendra P S Negi; Anand N Srivastava
Journal:  Respirology       Date:  2010-02       Impact factor: 6.424

7.  Changes in clinical presentation and staging of lung cancer over two decades.

Authors:  Virginia Leiro-Fernández; Cecilia Mouronte-Roibás; Cristina Ramos-Hernández; Maribel Botana-Rial; Ana González-Piñeiro; Esmeralda García-Rodríguez; Cristina Represas-Represas; Alberto Fernández-Villar
Journal:  Arch Bronconeumol       Date:  2014-05-09       Impact factor: 4.872

8.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

9.  IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients.

Authors:  Giovanna E Carpagnano; Antonio Spanevello; Claudia Curci; Francesco Salerno; Grazia P Palladino; Onofrio Resta; Giuseppe Di Gioia; Francesco Carpagnano; Maria P Foschino Barbaro
Journal:  Oncol Res       Date:  2007       Impact factor: 5.574

10.  Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study.

Authors:  D M Skillrud; K P Offord; R D Miller
Journal:  Ann Intern Med       Date:  1986-10       Impact factor: 25.391

View more
  9 in total

Review 1.  Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights.

Authors:  Esther Barreiro; Víctor Bustamante; Víctor Curull; Joaquim Gea; José Luis López-Campos; Xavier Muñoz
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 2.  Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.

Authors:  Ilaria Marrocco; Fabio Altieri; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

3.  Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.

Authors:  Hai-Xing Zhu; Lin Shi; Yong Zhang; Yi-Chun Zhu; Chun-Xue Bai; Xiang-Dong Wang; Jie-Bai Zhou
Journal:  J Transl Med       Date:  2017-03-24       Impact factor: 5.531

4.  Nelumbo nucifera leaves extracts inhibit mouse airway smooth muscle contraction.

Authors:  Xiao Yang; Lu Xue; Qingyang Zhao; Congli Cai; Qing-Hua Liu; Jinhua Shen
Journal:  BMC Complement Altern Med       Date:  2017-03-20       Impact factor: 3.659

5.  Lycopene prevents carcinogen-induced cutaneous tumor by enhancing activation of the Nrf2 pathway through p62-triggered autophagic Keap1 degradation.

Authors:  Siliang Wang; Yuan-Yuan Wu; Xu Wang; Peiliang Shen; Qi Jia; Suyun Yu; Yuan Wang; Xiaoman Li; Wenxing Chen; Aiyun Wang; Yin Lu
Journal:  Aging (Albany NY)       Date:  2020-05-04       Impact factor: 5.682

6.  Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Xuejie Wang; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2019-09-04       Impact factor: 6.639

7.  Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies.

Authors:  Elvin S Cheng; Marianne F Weber; Julia Steinberg; Karen Canfell; Xue Qin Yu
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-27       Impact factor: 4.322

8.  Oxidant status, iron homeostasis, and carotenoid levels of COPD patients with advanced disease and LTOT.

Authors:  M Kentson; P Leanderson; P Jacobson; H L Persson
Journal:  Eur Clin Respir J       Date:  2018-03-09

9.  Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Liyun Qin; Mercé Mateu-Jiménez; Xavier Duran; Lara Pijuan; Alberto Rodríguez-Fuster; Rafael Aguiló Espases; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.